PTCT earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -33.59. Updated 2026-07-23.
PTC Therapeutics (PTCT) Research Hub
PTC Therapeutics (PTCT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 66.06 USD (-2.23%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -33.59, market cap 6.46B. This hub links to the full technical, earnings and options research available for PTCT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 66.06 USD (-2.23%) |
| 52-week range | 64.57 USD – 90.87 USD |
| Trend regime | Range |
| 14-day RSI | 33 (Bearish) |
| Trailing P/E | -33.59 |
| Market cap | 6.46B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for PTCT
Covered Call on PTCT: how it works, illustrative setup around the real 66.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PTCT: how it works, illustrative setup around the real 66.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PTCT: how it works, illustrative setup around the real 66.06 USD price, max profit/loss, breakeven and when to use it. Educational.
PTCT technical analysis: range, last 66.06 USD, RSI 33, 52w range 64.57 USD–90.87 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PTCT in?
PTC Therapeutics (PTCT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PTCT in an uptrend or downtrend?
As of 2026-09-11, PTCT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PTCT's trailing P/E ratio?
PTCT's trailing P/E is -33.59, with a market cap of 6.46B. See the earnings research page for full valuation detail.
When does PTCT next report earnings?
PTCT is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of 0.22 USD.